← Back to headlines
BioMarin Pharmaceutical's Alesta Deal Boosts Rare Disease Growth
BioMarin Pharmaceutical's Alesta deal is expected to add new growth potential in the rare diseases sector for the company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Wizz Air Offers to Take Over TAROM's Domestic Routes, Sparking Controversy
23m ago
Guggenheim Investments Considers Buying Its Beleaguered Loan Amid Federal Probe
34m ago
Alpha Metallurgical Resources Directors Acquire Millions in Shares
34m ago
Football Clubs' Champions League Aspirations and Earnings
40m ago